Have any questions? 706-721-6582 or cts@augusta.edu
- INX-315-01: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients with Advanced Cancer
Clinical Trial
INX-315-01: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients with Advanced Cancer
To determine the safety and tolerability of INX-315 monotherapy and in combination with fulvestrant in adult patients with HR+/HER2- advanced or metastatic breast cancer.
Eligibility Criteria
- Inclusion Criteria At least 18 years of age One of the following advanced cancer types HR+/HER2- Breast Cancer Ovarian/ fallopian/ primary peritoneal cancer Confirmed diagnosis of advanced or metastic solid tumor that has progressed after prior standard therapy ECOG score of 0 or 1 Not pregnant, agrees to contraceptive use Exclusion Criteria Rapid disease progression Previous treatment with a CDK2/4/6 inhibitor Clinically significant heart, lung, bleeding, or central nervous system conditions. HIV, Hepatitis, or other uncontrolled infective Diagnosis
RESEARCH. INNOVATION. DISCOVERY.